Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis

Eur Respir J. 2018 Mar 22;51(3):1702490. doi: 10.1183/13993003.02490-2017. Print 2018 Mar.

Onno W Akkerman^{1

2

3}, Floris Grasmeijer^{4

3}, Wiel C M de Lange^{5

2}, Huib A M Kerstjens⁵, Gerard de Vries^{6

7}, Mathieu S Bolhuis⁸, Jan-Willem Alffenaar⁸, Henderik W Frijlink⁴, Grace Smith⁹, Roger Gajraj¹⁰, Rina de Zwaan¹¹, Paul Hagedoorn⁴, Martin Dedicoat¹², Dick van Soolingen^{11

13}, Tjip S van der Werf^{5

14}

¹ University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands [email protected].
² University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands.
³ Both authors contributed equally.
⁴ University of Groningen, Dept of Pharmaceutical Technology and Biopharmacy, Groningen, The Netherlands.
⁵ University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.
⁶ KNCV Tuberculosis Foundation, Den Haag, The Netherlands.
⁷ Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
⁸ University of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
⁹ National Mycobacteriology Reference Unit, Birmingham, UK.
¹⁰ Public Health England, Birmingham, UK.
¹¹ National Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
¹² Dept of Infection, Heart of England Foundation Trust, Birmingham, UK.
¹³ Radboud University Nijmegen Medical Centre, Depts of Pulmonary Diseases and Medical Microbiology, Nijmegen, The Netherlands.
¹⁴ University of Groningen, University Medical Center Groningen, Dept of Internal Medicine, Groningen, The Netherlands.

Abstract

Crossing borders by treating a patient with difficult to treat XDR-TB; highly individualised but holistic approach http://ow.ly/JyjK30ielsD